The Gale laboratory group conducts research and training aimed to define how virus and host, and microbe and host, trigger and control innate immunity for the outcome of infection and immunity. The group has been instrumental in defining the RIG-I-like receptor (RLR) pathway and innate immune triggering by virus infection. Gale lab research includes a focus to determine how innate immunity propagates and is regulated over the course of RNA virus infection, featuring virus regulation of innate immune signaling. They also conduct research to determine how innate immunity polarizes the immune response for protection and recovery from virus infection. More recently the group has also engaged in studies of Mycobacteria tuberculosis (Mtb) infection and disease. Gale lab activities include a strong training emphasis in innate immunity, RNA virus infection, and epidemic outbreak response actions. The group studies a range of emerging and contemporary viruses including Zika virus, HIV, SIV, SARS-CoV-2, West Nile virus, dengue virus, Japanese encephalitis virus, hepatitis C virus, hepatitis B virus, hantavirus, influenza A virus, chikungunya virus, and Oopouche virus. Studies in the lab focus on applying systems biology approaches and functional genomics toward defining therapeutic targets for immune enhancement to control emerging and pathogenic RNA virus infection and Mtb infection and disease. Dr. Gale leads a diverse faculty at the University of Minnesota, Department of Microbiology and Immunology, and in the University of Minnesota Institute on Infectious Disease. These colleagues focus on understanding host/pathogen interactions, infection and immunity, microbial dynamics, and on defining and responding to infectious disease outbreaks and implementing infection intervention. Studies of virus infection, innate immune actions, and innate immune therapeutics will be presented.